Truenat HIV1/HIV 2 will detect and quantitatively diagnose HIV types 1 and 2 with a sample-to-result time of one hour
Molbio Diagnostics has launched a new test for differential diagnosis of HIV 1 and HIV 2 with viral loads within 60 minutes. The test works on the existing Truelab infrastructure and will require no additional set-ups and equipment.
Commenting on the launch, Sriram Natarajan, CEO, Founder and Director, Molbio Diagnostics, said, “HIV continues to be a major public health concern impacting people and economies. Since the disease is not curable, screening and early testing are critical to stop the spread of HIV. At the same time WHO has mandated that patients on treatment must be monitored only by viral load testing. Being a point of care platform Truenat HIV 1/ HIV 2 will provide universal access to both early detection and viral load estimation.”
Also commenting on the launch, Dr Chandrasekhar Nair, CTO and Director, Molbio Diagnostics said, “For any disease, early detection is always the key to stop its spread. HIV was first identified more than 50 years ago, and we don’t have a cure yet. So testing is the first step to preventing the further spread of the disease. We needed an effective means of testing at point-of-care, which is cost-effective and has a short sample-to-result time. We’ve achieved that with Truenat. Truenat HIV1/HIV2 can provide test results in an hour, assuring early and accurate diagnosis of the infection.”
Truenat is a point-of-care portable, battery-operated, IoT-enabled, Real Time PCR platform with a sample-to-result time of less than 1 hour. The platform can test over 35 diseases, including COVID-19, TB, hepatitis, HIV, HPV, dengue, malaria, etc.
- Advertisement -